RFV-20063-92041
4 vaccinations
1 coded response
13 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 981 / WA
- Registered
- 2022-10-01
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-11
Dose 1 — Pfizer-BioNTech
-
2021-03-28
Dose 2 — Pfizer-BioNTech
-
2021-11-10
Dose 3 — Pfizer-BioNTech
-
2022-10-01
Registered in v-safe
-
2022-10-01
Dose 4 — Moderna
- 2022-10-01
-
2022-10-02
Health check-in — days 1–6 daily, dose 4Feeling: Poor · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to do your normal daily activitiesAdult check-in
- 2022-10-03
- 2022-10-05
- 2022-10-07
- 2022-10-08
- 2022-10-15
- 2022-10-22
- 2022-10-29
- 2022-11-05
- 2022-11-13
-
2022-12-31
Survey response — 3 months, dose 4MedDRA: Headache, Oropharyngeal pain, Pyrexia — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Sore throat, fever, headacheMedDRA releases: 2024-11 · check-in free text available
- 2023-04-01
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-11 | Pfizer-BioNTech | No |
| 2 | 2021-03-28 | Pfizer-BioNTech | No |
| 3 | 2021-11-10 | Pfizer-BioNTech | No |
| 4 | 2022-10-01 | Moderna | No |
Free text
Release 12 — 3 months, dose 4
Symptoms: Sore throat, fever, headache
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Headache | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release